CWNM’s Technology Looking To Re-Shape The Pharma Industry

Recommended Stock Newsletters
 
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

allpennystocks Newsletter

You can read the original version online:

http://ymlp271.net/zCzWWo ——————————————————————————– February 12, 2013 Penny Stock Snapshot ….

Two Small-Cap Stocks Head and Shoulders Above Peers with New Drug Delivery Systems (OTCQB: CWNM) “Taking a more unique approach, which drastically limits competition, and coming in with a far less expensive price tag per share, Crown Marketing Pharmaceuticals (OTCQB:CWNM) purports to have the “most advanced, yet elegantly simple approach to Controlled Drug Delivery.” The company’s CDDT (Controlled Drug Delivery Technology) is a patented delivery system built upon mathematically programming the rate of diffusion to deliver medications over a specified period of time.” Latest News Release (http://finance.yahoo.com/news/crown-marketing-reviews-positive-vivo-130000532.html) Quote & News (http://app.quotemedia.com/quotetools/clientForwardtargetURL=http://www.baystreet.ca/quotedata/partners/allpennystocks/quotes.asp&action=showDetailedQuote&symbol=CWNM) CWNM Snapshot The pharmaceutical business is starving for new therapies and technologies to shepherd in the next wave of treatments to combat diseases. Subsequently, large pharmaceutical companies are dolling-out increasing amounts of money to try and get an edge on competitors as they slowly fall one by one off the so-called patent cliff, costing them billions of dollars annually as blockbuster drugs lose protection from generics.

Make no mistakes about it; the cliff is steep and expensive. Of the $860 billion in global sales of pharmaceuticals in 2010, 133 drugs accounted for about 34 percent, or nearly $300 billion, of total sales. 13 of those drugs, or 9.8 percent, face patent expiration in the next five years. In 2013 alone, Evaluate Pharma estimates drugs generating $29 billion annually will lose patent protection. Included in this group are Eli Lilly & Co.’s (NYSE:LLY) antidepressant Cymbalta and diabetes drug Humalog, Biogen Idec Inc.’s (Nasdaq:BIIB)multiple sclerosis drug Avonex (although Biogen contests that it has extended the patent) and Purdue Pharma’s chronic pain drug OxyContin.

Taking the hit in 2012 were drugs such as Sanofi SA’s (NYSE:SNY) blockbuster blood thinner Plavix and Pfizer Inc.’s (NYSE:PFE) cholesterol drug Lipitor, which accounted for almost 16 percent of Pfizer’s total drug sales in 2010.

As the competition continues to stiffen in drug development, another pathway to prosperity that is catching the attention of the investment community is through improvements in drug delivery systems, or the means to get therapeutics into the body. These new technologies address fundamental challenges of pharmaceutical companies not only in developing novel therapeutics, but also potentially extending intellectual property rights on existing drugs.

Many companies are still relying upon dissolvable coatings or hydrophilic matrix processes to deliver drugs over time, but the next generation of drug delivery entails many different methodologies that appear far superior. For example, Unilife Corporations (Nasdaq:UNIS) is focused on innovative injectable drug delivery systems and owns a broad portfolio of proprietary device technologies entrenched in the injectable arena. Corporate products include prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors and more.

The company has developed new bolus injectors, a new class of disposable, wearable devices for the subcutaneous administration of high-dose volume or high viscosity biologics. For manufacturers of peptides and other types of biologics, getting the correct recipe of volume and viscosity for drug delivery can be a significant hurdle, a problem that Unilife is remedying with its auto-injector.

Once called “patch-pumps” or similar, the new age of devices have been re-branded as bolus injectors and are far superior to legacy models in delivering a precise dose over a designated time frame and can handle a wide range of viscosity levels. Once used the devices are simply disposed.

Not only do the bolus injectors offer an opportunity for Unilife to penetrate traditional markets for existing drugs by providing a potential alternative to drugs relegated now to delivery only in IV format in a clinical setting, they, importantly, position the company to provide options for pharmaceutical companies looking to develop drugs in larger doses or concentrations.

Only one component of Unilife’s portfolio, the company estimates the bolus injector market alone could breach the $500 million mark in the next few years. The company does face challenges pertaining to breaking into the market and from stiff competition across several of their products. Fighting for market share in the same space are other small caps like Retractable Technologies Inc. (AMEX:RVP) and bigger Antares Pharmaceutical, Inc. (Nasdaq:ATRS), a company that Mad Money’s Jim Cramer said he didn’t like how competitive the industry is.

Taking a more unique approach, which drastically limits competition, and coming in with a far less expensive price tag per share, Crown Marketing Pharmaceuticals (OTCQB:CWNM) purports to have the “most advanced, yet elegantly simple approach to Controlled Drug Delivery.” The company’s CDDT (Controlled Drug Delivery Technology) is a patented delivery system built upon mathematically programming the rate of diffusion to deliver medications over a specified period of time.

With its CDDT, Crown has bridged a wide gap left by traditional methods of ingestible drug delivery and developed a technology that could revolutionize the pill industry. Why Because today’s technologies of coating medications only work when the coating stays intact. Cracks or breaks can present a significant health risk to the patient. Hydrophilic matrices, which rely upon stomach acids and fluids to breakdown the matrix and release the medication, do not account for differences in individual patient’s bodies, presenting a risk of toxicity or decreased bioavailability of the medication.

In layman’s terms, while there have been some advancements in oral drug delivery, the standard of care today still doesn’t work right.

Crown Marketing Pharmaceuticals realized the weaknesses and has built a better mousetrap.

Harnessing the principals of Chaos Theory and chemical potentials and applying them to a new manufacturing process, Crown’s platform is demonstrating a far superior spectrum and reliability of pharmacokinetic profiles. Crown’s technology is based on the observation that a device coated with an impervious membrane, with one or more orifices and of a defined geometry, releases molecules in an organized, predictable, and controllable manner utilizing compound-specific chemical potential energy along gradients. The modeling equations take into consideration the basic laws of diffusion, as well as the biochemical profiles of the drugs and excipients tested.

What the CDDT delivers is a high level of flexibility for pharmaceutical or neutraceutical manufacturers in matching chronotherapeutic requirements without significant investment in new manufacturing machinery or complex chemical diffusion matrix formulations.

Crown has validated its technology through in vitro and in vivo experiments demonstrating the ability to generate nearly-constant and controlled concentrations of drug at the orifice over a selected period of time. Mathematical modeling makes the release kinetics extremely predictable, while the novel design permits controlling kinetics at both ends of the delivery period, allowing fine-tuning of the kinetic profile to match pharmacodynamic expectations (including the magnitude of initial bolus and duration of release).

The possible uses for this technology canvas every pill that is ingested, giving it a particularly impressive – and somewhat unprecedented – upside. The company said on January 31 that it is also targeting the lucrative diabetes industry after completing laboratory research with positive results using its CDDT with Metformin, the most widely prescribed diabetes drug on the market today. Although the most commonly administered, patients have notoriously complained about the side effects, such as diarrhea, nausea and vomiting, and the bad taste and odor of Metformin. Because of the CDDT, Crown believes that it can reduce many of these unpleasant side effects.

Global Metformin sales totaled $1.6 billion in 2012.

The broad range of benefits, endless applications and novel nature of Crown’s technology seems to give it a competitive advantage over any peers. As aforementioned, big pharma is hungry to re-stock dwindling portfolios and revenue streams. The CDDT promises precise targeting and more therapeutic benefits, potentially leading to decreased dosages, reduced side effects and a means to breathe life into the cash cows that typically contract by at least 50 percent upon patent expiration.

These are two game-changing technologies offered by companies with tiny market valuations compared to potential, making them worthy of a far closer examination. Proper due diligence is, as always, encouraged.

Read the full write-up on CWNM by clicking here: (http://www.allpennystocks.com/aps_us/special-reports/333/two-small-cap-stocks-head-and-shoulders-above-peers-with-new-drug-delivery-systems.htm).

OVERVIEW Crown`s Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles of diffusion through precise mathematical formulas.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations.

Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

Corporate Information * Exchange: OTCQB * Market Cap: 20.9 Million * Outstanding Shares: 190.1 Million * Price: $0.11 * 52 Week Low / High:$0.085 / $1.01 * Information As Of February 12, 2013 Useful Profile Links * Company Website ( http://crowncddt.com/ ) * Recent News & Press Releases ( http://app.quotemedia.com/quotetools/clientForwardtargetURL=http://www.baystreet.ca/quotedata/partners/allpennystocks/quotes.asp&action=showDetailedQuote&symbol=CWNM ) Forward Looking Statements This report includes forward-looking statements that reflect Crown Marketing current expectations about its future results, performance, prospects and opportunities. Crown Marketing has tried to identify these forward-looking statements by using words and phrases such as “may,” “will,” “expects,””anticipates,” “believes,” “intends,” “estimates,” “plan,” “should,” “typical,””preliminary,” “we are confident” or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Crown Marketing`s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company`s growth expectations and ongoing funding requirements, and specifically, the Company`s growth prospects with scalable customers, and those outlined above. Other risks include the Company`s limited operating history, the Company`s history of operating losses, consumers`sacceptance, the Company`s use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company`s securities, the possible volatility of the Company`s stock price, the concentration of ownership, and the potential fluctuation in the Company`s operating results.

Disclaimer AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable.

For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Crown Marketing The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2013 AllPennyStocks.com. All rights reserved.

AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes.

Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated three thousand two hundred fifty dollars by a third-party, OTC Stock Review for its efforts in presenting this CWNM report on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain”forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be”forward looking statements.” Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as“expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com.

Readers can review all public filings by companies at the SEC`s EDGAR page. The NASD has published information on how to invest carefully at its web site.

_____________________________ Change email address / Leave mailing list: http://ymlp271.net/ugjheqmgsgeyyqygubbwggmqbybw Powered by YourMailingListProvider

 
This entry was posted in AllPennyStocks and tagged , , , , , , , . Bookmark the permalink.

Comments are closed.